Old Web
English
Sign In
Acemap
>
Paper
>
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
2021
Kate C Tatham
Manu Shankar-Hari
Yaseen M. Arabi
Keywords:
pain medicine
Anesthesiology
Interleukin receptor
Coronavirus disease 2019
Medicine
Internal medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
15
References
0
Citations
NaN
KQI
[]